Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Colorectal Neoplasms 30Carcinoma, Hepatocellular 17Ovarian Neoplasms 14Fallopian Tube Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Neoplasms 8Glioblastoma 7Liver Neoplasms 6Lung Neoplasms 5Colonic Neoplasms 5Breast Neoplasms 5Neoplasm Metastasis 4Carcinoma, Renal Cell 4Brain Neoplasms 4Stomach Neoplasms 3Rectal Neoplasms 3Melanoma 3Carcinoma, Ovarian Epithelial 3Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Nasopharyngeal Neoplasms 2Nasopharyngeal Carcinoma 2Lymphoid Interstitial Pneumonia 2Colorectal Cancer Metastatic 2Brenner Tumor 2Adenocarcinoma, Mucinous 2Virus Diseases 1Venous Thrombosis 1

Interventions

pembrolizumab 1Taxes 1Paclitaxel 1Nivolumab 1Ipilimumab 1Immunoglobulin G 1Gemcitabine 1Docetaxel 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Adenocarcinoma, Clear Cell × Bevacizumab × Clear all
NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡